205 results about "Cell targeting" patented technology

A compound or molecular complex. The compound or molecular complex comprises: a metal chelator configured for chelation with a radioactive isotope or a non-radioactive isotope; and a trifluoroborate (BF3)-containing moiety configured for 19F / 18F exchange or a precursor thereof; and optionally a cell-targeting domain.

The invention discloses a preparation method of a nuclear magnetic resonance imaging contrast agent based on surface hepatocyte targeting molecule modification ferroferric oxide nanoparticles, which comprises the following steps: synthesizing ferroferric oxide nanoparticles (Fe3O4 NPs) by a thermal decomposition method, and connecting the Fe3O4 NPs with a ligand dopamine-PEG2000-EOB carrying hepatocyte targeting molecules by a ligand exchange method to obtain the nuclear magnetic resonance imaging contrast agent. The nanoparticles Fe3O4-EOB-PEG capable of carrying out selective T2 nuclear magnetic resonance imaging on the hepatocytes are formed. The method is simple and easy to operate, the controllability of the preparation process is high, the biocompatibility of the obtained product is good, T2 signals of hepatocytes can be remarkably improved, the good early diagnosis effect on liver tumors is achieved, and wide application prospects are achieved.

The invention discloses an emulsifier for preparing a Pickering emulsion, the Pickering emulsion as well as a preparation method and application of the Pickering emulsion. The emulsifier of the Pickering emulsion is obtained by dissolving distearoyl phosphatidylcholine, cholesterol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 in ethanol, carrying out rotary evaporation to remove ethanol, then adding an antigen aqueous solution containing an antigen, continuing rotary evaporation to obtain liposome nanoparticles, heating the liposome nanoparticles with mannose in a water bath, and carrying out freeze drying. The Pickering emulsion is obtained by dispersing an emulsifier in water as a water phase, taking squalene as an oil phase, mixing the water phase and the oil phase, and homogenizing. The Pickering emulsion disclosed by the invention is prepared by taking antigen presenting cell targeted liposome nanoparticles as a raw material; and the antigen has excellent ion concentration characteristic, pH stability, temperature stability and storage stability, and can protect the integrity of the antigen.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and / or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

The invention discloses a prebiotic-loaded intestinal targeting exosome and a preparation method and application thereof.The preparation method comprises the steps that firstly, plasmids containing intestinal cell targeting peptide sequences are constructed through a gene editing technology, the plasmids are transfected and introduced into cells, the transfected cells are screened with antibiotics, and cell strains stably expressing intestinal cell targeting peptides are obtained; then culturing and adding prebiotics, and continuously culturing to enable the cells to take in the prebiotics and release the exosomes loaded with the prebiotics; and finally, collecting cell culture supernate, and centrifuging and resuspending for multiple times under a low-temperature condition to obtain the prebiotics-loaded intestinal targeting exosome. According to the preparation method, extraction of the exosome, loading of the prebiotics and an intestinal targeting modification process are optimized, so that the prepared intestinal targeting exosome loaded with the prebiotics can be used for remarkably improving the loading efficiency and intestinal targeting of the prebiotics and enhancing the stability of the exosome in gastrointestinal tracts; therefore, the delivery efficiency and the treatment effect of the prebiotics in the intestinal tract are improved.

The application provides an improved hyaluronic acid injection preparation for inflammation targeting and stem cell capture, a preparation method and use thereof, and belongs to the field of medicine. The injection preparation is prepared from unsaturated bond modified hyaluronic acid, stem cell targeting DNA tetrahedron and thiol modified inflammation targeting aptamer as raw materials. The injection preparation can be targeted to accumulate at an osteoarthritis site, capture mesenchymal stem cells in situ, recruit mesenchymal stem cells to the osteoarthritis site, promote differentiation of stem cells into cartilage, promote cartilage repair, play a role in treating osteoarthritis, and has a good application prospect.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

A method for determining if an agent is suitable for treating a Rheumatoid Arthritis (RA) patient, the method comprising determining the profile of a first, second and / or third marker panel in a sample from the patient, wherein the agent is selected from an agent that downregulates TNF mediated signalling, an agent that downregulates IL-6 mediated signalling and a B cell targeted therapy.

The application relates to a T cell-targeting nanoparticle based on a nucleic acid aptamer and a preparation method and application thereof, in particular to a T cell-targeting lipid aptamer, wherein the lipid aptamer comprises a hydrophobic molecule and a nucleic acid aptamer, the nucleic acid aptamer comprises at least one nucleic acid aptamer for targeting a T cell surface molecule, and the molar ratio of the hydrophobic molecule and the nucleic acid aptamer is 5000:1-1:10. The lipid aptamer or the nanoparticle formed by self-assembly technology of the lipid aptamer can realize cell 'pointing' gene modification and in-vivo gene reprogramming of cells.

The invention relates to a CAR-T (Chimeric Antigen Receptor-T) cell targeting SLC7A11.

The invention belongs to the technical field of biological medicines, and discloses a B cell and cartilage cell senescence targeting osteoarthritis treatment medicine. The invention provides an application of an anti-MIF antibody or an antigen binding fragment thereof as a B cell targeting immunomodulator in osteoarthritis treatment drugs, the anti-MIF antibody or the antigen binding fragment thereof regulates and controls an MIF / HMGB1 / MMP13 signal axis through a neutralization effect with MIF, so that the MIF and B cells are significantly co-localized, expression of HMGB1 in the B cells is promoted, and the osteoarthritis treatment effect is improved. The senescence of B cells is reduced and the B cells are promoted to regulate or repair phenotype transformation so as to destroy chronic inflammatory circulation and diffusion of pathogenic plasma cells, and the expression of MMP13 in joint tissues is reduced so as to maintain the steady state of cartilage tissues; the preparation method has an excellent application prospect in preparation of an OA intra-articular injection drug which realizes rapid anti-inflammatory and long-term cartilage protection effects and can realize a lasting curative effect through low-frequency drug delivery.

The invention discloses a regulation mechanism research method of depleted precursor CD8T cells, and relates to the field of immunology and molecular biology. Comprising the following steps: detecting the expression level of the ARHGAP9 gene in a chronic virus infection model; constructing a T cell specific ARHGAP9 gene knockout animal model; the influence of ARHGAP9 deletion on the frequency, phenotype and function of the Tpex cell is analyzed; a single cell transcriptome sequencing technology reveals that ARHGAP9 regulates and controls a downstream signal channel of a Tpex cell. By constructing a chronic virus infection model, detecting the expression dynamic state of the ARHGAP9 gene, knocking out an animal model by utilizing T cell specificity ARHGAP9, and combining flow cytometry, qPCR, single cell transcriptome sequencing and other technologies, the invention discloses the effect of the ARHGAP9 as a novel immune checkpoint molecule, and provides a theoretical basis for developing Tpex cell targeting immunotherapy.

Two plasmids are transformed in the bacterium, one plasmid is a gene editing plasmid which is used for expressing CRISPR / Cas9 gene editing tools in the bacterium, the sgRNA sequence is shown in SEQ ID NO.1, and the other plasmid is an X174E-CKS9 expression plasmid which is used for expressing targeting peptide shown in SEQ ID NO.2 and IPTG (isopropyl-beta-d-thiogalactoside) induced expression splitting gene X174E in the bacterium. The invention further discloses a cracking vesicle obtained after induction of the engineering bacterium and application of the cracking vesicle. CKS9-loaded lysing vesicles with M cell targeting are generated in situ, and a gene editing tool is transferred to antigen presenting cells by using the characteristic that the M cells can completely transfer antigens to lymphatic follicles. Compared with a strategy of mannose modification and other targeted antigen-presenting cells, the method has the advantages that the targeting property is more accurate, and a new choice is provided for the antigen-presenting cells of targeted intestinal tracts.

The present disclosure concerns genetic modification of fibroblasts or fibroblast-derived materials (including of the fibroblasts from which the fibroblast-derived materials are derived). In specific aspects, they are modified such that they may express one or more surface markers that allow targeting to a tissue and / or organ of interest. In some aspects, they are modified such that they may lose one or more surface markers that then allow targeting to a tissue and / or organ of interest. In certain aspects, one or more surface markers are modified that then allows targeting to a tissue and / or organ of interest.

The invention relates to the technical field of production of nano composite materials, in particular to space heterostructure ferrite nano particles with a hepatocyte targeting function and a preparation method of the space heterostructure ferrite nano particles. According to the nanoparticles, a core layer and a shell layer are doped with metal elements in a gradient manner, and a ligand layer with a hepatocyte targeting function is modified, so that a physical-chemical three-layer composite system with a spatial heterostructure is formed. According to the magnetic resonance imaging contrast agent prepared on the basis of the spatial heterogeneous distribution of gradient doping of the ferrite nanoparticles by regulating and controlling the types and concentrations of doping elements, the enrichment effect and the local recognition capability in a liver region can be remarkably enhanced, the relaxation rate of the ferrite nanoparticles is effectively increased, and the magnetic resonance imaging contrast agent has a good application prospect. The contrast ratio, the imaging speed and the effective imaging time window of living liver and gall imaging are optimized, and meanwhile, the biocompatibility and the metabolic performance of the material are improved.

Disclosed is a method for editing mitochondrial DNA (mtDNA) within a cell, which include introducing into the cell (a) a DNA cleaving enzyme targeted to the mtDNA sequence to be deleted; (b) a first DNA binding component targeted to a sequence adjacent to the 5′ end of a mtDNA sequence to be deleted; and (c) a second DNA binding component targeted to a sequence adjacent to the 3′ end of the mtDNA sequence to be deleted, where the DNA cleaving enzyme generates a double stranded break (DSB) within the mtDNA sequence to be deleted or generates a single strand nick on the light strand of the mtDNA sequence to be deleted, and wherein the mtDNA sequence between the target sequence for the first DNA binding component and the target sequence for the second DNA binding component is deleted.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

Provided herein are compositions comprising a muscle (cardiac and / or skeletal) cell targeting peptide linked to or inserted into a targeting protein of a recombinant vector having at least one exogenous peptide comprising Xn-RGD-n-mer-Xm. Compositions providing such conjugates, targeting peptides, or recombinant vectors with engineered capsid or envelope proteins are provided, along with uses thereof.

Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.

Provided herein are immuno-responsive cells expressing a B cell targeting pCAR comprising a 2nd generation chimeric antigen receptor (CAR) and a chimeric co-stimulatory receptor (CCR). Also provided herein are methods of preparing the immuno-responsive cells and methods of directing T cell mediated immune response using the immuno-responsive cells.

This invention relates to a polypeptide for gene delivery, a polypeptide / nucleic acid molecular complex prepared therefrom, and its applications. The polypeptide of this application has the structure shown in Formula I, wherein Formula I contains an immune cell targeting group represented by Y. The polypeptide developed in this application, as a gene delivery carrier, has a highly efficient nucleic acid loading capacity. Furthermore, it exhibits high delivery efficiency to immune cells both in vitro and in vivo, thus showing broad application prospects in the immune cell-targeted delivery of genes.

The present invention relates to a polymer self-assembly nanocarrier and a method of preparing same, the nanocarrier binding a peptide that targets a specific cell and, simultaneously, carrying an active ingredient that has been verified. The present invention can exhibit various effects such as a moisturizing effect, an increase in filaggrin production, whitening, skin barrier reinforcement and the like by selectively and efficiently delivering a drug through a targeting peptide, can be applied to skin diseases such as atopy or psoriasis, and is expected to enable the maximum effect of an active substance in the pharmaceutical and cosmetic fields to be obtained.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

The invention discloses a coupling molecule with an effect of promoting macrophages to selectively swallow extracellular goods as well as a preparation method and application of the coupling molecule, and belongs to the technical field of biological medicines. The coupling molecule disclosed by the invention is a double-targeting polypeptide and consists of a macrophage targeting peptide fragment, a linker and a target cell targeting peptide fragment, wherein the target cell targeting peptide fragment comprises peptide fragments targeting tumor cells and apoptotic cells. One end of the dual-targeting polypeptide is connected with macrophages, the other end of the dual-targeting polypeptide is connected with tumor cells / apoptotic cells, and the interaction between the macrophages and the tumor cells / apoptotic cells is improved in a molecular glue mode. Aiming at tumor cells, the dual-targeting polypeptide can enhance the phagocytosis and killing effects of macrophages on the tumor cells under the action of a CD47 antibody, so that the anti-tumor effect is achieved; aiming at apoptotic cells, the dual-targeting polypeptide can promote the interplant effect of macrophages, so that the anti-inflammatory effect is achieved. Therefore, the dual-targeting polypeptide disclosed by the invention has relatively good drug development potential.

The invention provides a targeted mRNA delivery system of muscle tissues and / or muscle cells based on aptamer functionalized LNP (Apt-LNP), the delivery system can significantly improve mRNA transfection of the muscle tissues, and meanwhile, mRNA expression in main organs such as liver and spleen is greatly reduced. The expression intensity of muscle tissue in-situ mRNA is improved through modification of the aptamer, meanwhile, mRNA expression in main organs such as the liver and the spleen is greatly reduced, and side effects caused by off-target of mRNA infectious disease vaccines are expected to be avoided. The method is expected to be applied to the field of infectious disease mRNA vaccines The invention also provides a targeting mRNA delivery system of lymph node tissues and / or immune cells based on the aptamer functionalized LNP (Apt-LNP). Compared with an existing lymph node targeting system, the Apt-LNP modified by the aptamer not only can realize lymph node mRNA targeting, but also can further target immune cells, and is expected to be applied to the field of tumor mRNA vaccines to enhance the curative effect of tumor vaccines.

The application discloses a method for modifying phospholipids and application thereof in preparation of liver-targeted liposomes, relates to the field of drug delivery, and first utilizes cholate and mannose to modify phospholipid molecules DSPE-PEG 2000 respectively 2000 Two raw materials DSPE-PEG 2000 -CA and DSPE-PEG 2000 -MAN for synthesizing liposomes are synthesized, and then cholesterols, DSPC and DC-cholesterols are added in a certain proportion to obtain liposomes with liver targeting property, which have high cell safety and liver cell targeting property.

This invention discloses an antibody-engineered bone marrow stromal cell and its applications, belonging to the field of biomedical technology. Using bone marrow stromal cells as a biological carrier, this invention externally modifies them with immune checkpoint antibodies to form an antibody-coated engineered cell preparation, thereby achieving targeted and precise mitochondrial delivery of exhausted T cells. This cell preparation can be used in combination with other immunotherapies that can induce T cell exhaustion, such as tumor immunotherapies and CAR-T therapy, to help enhance their anti-tumor efficacy and duration of effect.

The invention belongs to the technical field of bioengineering, and provides a drug-loaded targeted nano platform for targeted delivery of ZIF-8 drug-loaded nanoparticles by macrophages, a preparation method and an application, aiming at the technical problem that complications are easily caused by the existing treatment means of endometriosis, so that the invention provides a drug-loaded targeted nano platform for targeted delivery of ZIF-8 drug-loaded nanoparticles by macrophages, and a preparation method and application of the drug-loaded targeted nano platform. According to the invention, the ZIF-8 nano-particles and the drugs aiming at the energy metabolism level are combined to be used as the carrier, so that endometriosis cells with acidic cell microenvironment can be targeted, drug controlled release can be realized in the acidic environment of lesions, and the effective uptake of the endometriosis cells to the drugs is enhanced, thereby effectively increasing the uptake rate and the drug concentration at the target position, and improving the curative effect of the drug on the endometriosis cells. Meanwhile, the distribution of the medicine in normal tissues or cells is reduced, and the toxic and side effects of the medicine are reduced; and through the design of combining the macrophages with the ZIF-8 nano-particle carrier, the drug targeting property of the ZIF-8 nano-particle carrier can be obviously improved.

Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.

A method for marking cancer-associated mutations includes applying a nanoparticle having cell-targeting moiety containing an miRNA associated with a specific cancer.